

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

NOVEN PHARMACEUTICALS, INC.  
AND MYLAN PHARMACEUTICALS INC.,  
Petitioners

v.

NOVARTIS AG AND LTS LOHMANN THERAPIE-SYSTEME AG,  
Patent Owners

---

*Inter Partes* Review IPR2014-00550<sup>1</sup>

U.S. Patent No. 6,335,031

**PETITIONERS' RESPONSE TO PATENT OWNERS' MOTION FOR  
OBSERVATIONS ON CROSS-EXAMINATION OF DR. SCHÖNEICH**

---

<sup>1</sup> Case IPR2015-00268 has been joined with this proceeding.

**Response to p. 1 ¶ 1:** The testimony cited by Patent Owners demonstrates neither that bond strength is theoretical nor “that a POSA would not have reasonably predicted that rivastigmine would undergo oxidative degradation” based on its structure as Patent Owners assert. (Paper 44 at 1.) Dr. Schöneich testified that the bond dissociation energies reported in Carey & Sundberg (“C&S”) (Ex. 1007) are “absolute values” and are “independent of the measurement.” (Ex. 1048 at 23:8-14, discussing ¶13 of Dr. Schöneich’s Reply Declaration (Ex. 1032), which reproduces bond dissociation energy values from C&S (Ex. 1007 at 683).) As Dr. Schöneich testified, the bond dissociation energy (i.e., bond strength) for a particular bond in a molecule is an inherent property of the molecule based on its chemical structure. (Ex. 1025 at 58:13-21.) Because rivastigmine has three structural features immediately adjacent to a particular carbon-hydrogen (“C-H”) bond, a POSA would have immediately identified this bond as especially weak and particularly susceptible to oxidation. (Ex. 1011 ¶¶ 12, 55; Ex. 1025 at 48:2-49:13, 73:17-76:22; Ex. 1032 ¶¶ 14-15.)

**Response to p. 1 ¶ 2:** The testimony cited by Patent Owners does not demonstrate “that a POSA would not have reasonably predicted that rivastigmine would undergo oxidative degradation” based on its structure as Patent Owners assert. (Paper 44 at 1.) Dr. Schöneich did not testify that C&S “provides *only* relative reactivities, not absolute reactivities of aromatic hydrocarbons” as Patent

Owners assert. (*Id.*, emphasis added.) It was Patent Owners’ questioning that related *only* to a single table in C&S that shows the relative reactivities of aromatic hydrocarbons. These relative reactivities are important to demonstrate that a C-H bond at a benzylic position, that is also a tertiary position (as in rivastigmine), is 67 times more reactive to oxygen than a C-H bond in a benzylic position alone. (Ex. 1032 ¶ 13, citing Ex. 1007 at 693.) Patent Owners further mischaracterize Dr. Schöneich’s testimony, because he also testified that C&S provides the absolute bond strengths of tertiary and benzylic C-H bonds in the table of bond dissociation energies and states that “Benzylic, allylic, and tertiary positions are especially susceptible to oxidation.” (Ex. 1032 ¶¶ 8, 10, 11, citing Ex. 1007 at 683, 693.) This testimony demonstrates that a POSA would have reasonably predicted that rivastigmine would undergo oxidative degradation based on its chemical structure because the POSA would have recognized that a particular C-H bond in rivastigmine is especially weak and therefore susceptible to oxidation.

**Response to p. 2 ¶ 1:** The testimony cited by Patent Owners does not demonstrate that “a POSA would not have reasonably predicted from its structure that rivastigmine would undergo oxidative degradation . . . or require an antioxidant” as Patent Owners assert. (Paper 44 at 2.) Dr. Schöneich testified that a POSA would understand that “oxidation reactions usually occur significantly slower” in the dry state. (Ex. 1048 at 70:7-20, *see also* Ex. 1032 ¶ 48) Thus, a

POSA would have understood that an antioxidant may not be necessary even for an oxidation-sensitive drug when is it formulated as a dry dosage form. (Ex. 1048 at 69:18-70:2, quoting Ex. 1032 ¶ 48.)

**Response to p. 2 ¶ 2, p. 5 ¶ 1, p. 12 ¶ 1:** Patent Owners’ assertions that Dr. Schöneich’s “structural theory is unproven” (Paper 44 at 2, 5-6) is not supported by the testimony cited by Patent Owners. Dr. Schöneich testified that a POSA would have immediately recognized that rivastigmine was particularly susceptible to oxidation due to the presence of *three structural features*<sup>2</sup> immediately adjacent to a C-H bond that a POSA would understand to cause that bond to be especially weak and therefore readily oxidized. (Ex. 1025 at 48:2-49:13; Ex. 1011 ¶¶ 12, 53-55; Ex. 1032 ¶¶ 7-15) The support for Dr. Schöneich’s opinion is drawn from a standard textbook, Carey & Sundberg (Ex. 1007), which identifies these same structural features as causing adjacent C-H bonds to be “especially weak” and therefore prone to oxidation. (Ex. 1032 ¶¶ 7-15; Ex. 1025 at 58:3-68:15.)

In addition, Dr. Schöneich provided nicotine as an example of a drug with

---

<sup>2</sup> Patent Owners mischaracterize Dr. Schöneich’s’ opinion by reciting only two of the three structural features identified by Dr. Schöneich that a POSA would have recognized as causing a particular C-H bond in rivastigmine to be especially weak and therefore particularly susceptible to oxidation. (Ex. 1011 ¶¶ 12, 55; Ex. 1025 at 48:2-49:13, 73:17-76:22; Ex. 1032 ¶¶ 14-15.)

the same three key structural features as rivastigmine that was known to undergo oxidation at the subject C-H bond and was known to oxidatively degrade in pharmaceutical formulations including transdermal patches. (Ex. 1025 at 84:17-89:20; Ex. 1026 at 452:1-5, 563:3-7; Ex. 1032 ¶¶ 46, 56-59.)

**Response to p. 2 ¶ 3:** Patent Owners' conclusion that "theoretical 'susceptibility' to oxidative degradation does not correlate with the pharmaceutical reality" (Paper 44 at 2-3) is not supported by the cited testimony. It was not merely an "assertion" of Dr. Schöneich's that the benzylic position is "especially susceptible to oxidation." Rather, Dr. Schöneich's testimony is supported by, and indeed quoted from, a standard chemistry textbook, Carey & Sundberg. (Ex. 1007 at 693.) Dextromethorphan was reported to be only "moderately stable" and had been observed to oxidatively degrade. (Ex. 1019 at 308; Ex. 1032 at 61.)

**Response to p. 3 ¶ 1 and p. 4 ¶ 1:** Patent Owners incorrectly assert that Dr. Schöneich mischaracterized the teachings of Boccardi 1994 (Ex. 2050) and Boccardi 1989 (Ex. 1019). As Dr. Schöneich testified, Boccardi 1989 states that dextromethorphan is only "moderately stable" and investigated the degradation of dextromethorphan they had previously observed and assumed was due to the presence of trace amounts of iron in glassware. (Ex. 1048 at 113:13-114:17; *see also* Ex. 1032 ¶ 61; Ex. 1019 at 308.) Boccardi 1994 states that the product of oxidative degradation (i.e., 10-ketodextromethorphan), was found in trace amounts

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.